HFrEF stands for heart failure with reduced ejection fraction, a condition in which the heart muscle has become too weak to pump blood effectively. Specifically, “reduced” means the left ventricle ejects less than 40% of its blood volume with each beat, compared to the roughly 55–65% a healthy heart manages.1PubMed. Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week It is the most studied form of heart failure, and the one for which the widest range of proven treatments exists. Understanding how it develops, what drives it forward, and what can be done about it matters because the condition is progressive but far from hopeless.
What Ejection Fraction Actually Tells You
Ejection fraction, or EF, is the percentage of blood the left ventricle pushes out each time it contracts. Doctors measure it with an echocardiogram, an ultrasound of the heart. Under revised classification schemes, an EF below 40% qualifies as “reduced,” an EF in the low-to-mid 40s is now called “mildly reduced,” and an EF at or above roughly 55% in men or 60% in women is considered normal.2PubMed. Classification of Heart Failure According to Ejection Fraction: JACC Review Topic of the Week These categories matter because the drug treatments proven to help differ substantially across them. Most of the landmark clinical trials that shaped modern heart failure therapy enrolled patients with EF below 35–40%, which is why the treatment toolkit for HFrEF is far richer than for preserved-EF heart failure.
EF is a useful number, but it is not the whole picture. Two patients with an EF of 30% can feel very different: one might be walking comfortably while the other is breathless at rest. That is because symptoms depend not only on how well the pump squeezes but also on fluid status, heart rate, kidney function, and how much the body has compensated. Still, EF remains the single most important number for deciding which treatments are appropriate.
Why the Heart Keeps Getting Weaker
When the heart’s pumping ability drops, the body treats it like an emergency. The sympathetic nervous system ramps up adrenaline-related signals, and the kidneys activate a hormonal cascade called the renin-angiotensin-aldosterone system (RAAS). In the short run, these responses prop up blood pressure and redirect blood flow to vital organs. In the long run, they backfire: the sustained hormonal overdrive causes the heart muscle to stiffen, enlarge, and develop scar tissue, while the kidneys retain salt and water, piling more volume onto an already struggling heart.3PubMed Central. Neurohormonal activation in heart failure with reduced ejection fraction
This vicious cycle of neurohormonal activation is now understood as one of the most important engines driving HFrEF forward.4PubMed Central. Neurohormonal Blockade in Heart Failure Nearly every major drug used to treat HFrEF works by interrupting some part of it, whether by blocking adrenaline’s effects on the heart, calming the RAAS, or reducing the volume of fluid the body retains. Understanding this single mechanism explains why HFrEF therapy relies so heavily on multiple medications used together: each one blocks a different arm of the same damaging process.
Common Causes
The leading cause of HFrEF is coronary artery disease. A large study of over 73,000 heart failure patients found that ischemic (blood-supply-related) causes were independently associated with HFrEF, while high blood pressure and valve disease were more closely tied to heart failure with preserved EF.5PubMed. Etiology of Heart Failure Across the Ejection Fraction Spectrum and Association With Prognosis In practical terms, a prior heart attack that damaged a section of heart muscle is the single most common path to HFrEF. But it is not the only one. Dilated cardiomyopathy, in which the heart muscle weakens without a clear blockage in the arteries, accounts for a large share of cases and can be triggered by viral infections, heavy alcohol use, certain chemotherapy drugs, or genetic factors. Valve disease, uncontrolled high blood pressure, and sustained abnormal heart rhythms round out the list.
How Doctors Confirm the Diagnosis
Beyond an echocardiogram to measure EF, blood tests play a key role. Two peptides released by the heart when it is under stress, BNP and NT-proBNP, are now considered the gold-standard biomarkers for confirming a heart failure diagnosis and estimating prognosis.6PubMed. Which biomarkers do clinicians need for diagnosis and management of heart failure with reduced ejection fraction? In patients with HFrEF, both peptides predict the risk of death and hospitalization with similar accuracy.7PubMed. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction
What makes these biomarkers especially useful is that they are not just a one-time snapshot. A rising NT-proBNP level over time is associated with worse survival, regardless of the starting value, and this holds true for both reduced-EF and preserved-EF heart failure.8Circulation. Abstract 14751: Rising NT-probnp Levels Are Associated With Reduced Survival in Patients With Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Reduced Ejection Fraction (HFrEF) Doctors use trending NT-proBNP levels to gauge whether treatment adjustments are working, essentially treating the number like a thermostat reading for the heart’s stress level.
The Four Pillars of Drug Therapy
Modern HFrEF management rests on four classes of medication, often referred to as the “four pillars.” Each one targets a different aspect of the disease, and the strongest evidence comes from using all four together rather than relying on any single drug. Each additional pillar a patient receives is linked to further improvement in heart size and pumping ability.9Association of Age With Guideline-Directed Medical Therapy and Left Ventricular Reverse Remodeling. Association of Age With Guideline-Directed Medical Therapy and Left Ventricular Reverse Remodeling
Neurohormonal Blockers: ARNi, Beta-Blockers, and MRAs
The first three pillars all work by dampening the neurohormonal overdrive described earlier. An angiotensin receptor-neprilysin inhibitor (ARNi), the combination of sacubitril and valsartan, is now preferred over older ACE inhibitors. In the landmark PARADIGM-HF trial, sacubitril/valsartan reduced the combined risk of cardiovascular death or heart failure hospitalization by about 20% and all-cause death by about 16% compared to enalapril, itself an active treatment.10PubMed Central. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial
Beta-blockers slow the heart rate and blunt the effects of adrenaline on the heart muscle. Three specific beta-blockers have been proven to reduce death in HFrEF: metoprolol succinate, carvedilol, and bisoprolol. The evidence for each is robust. The MERIT-HF trial of metoprolol succinate was stopped early after the drug cut all-cause mortality by about a third. Carvedilol showed a similar magnitude of benefit in the COPERNICUS trial, reducing mortality by about 34% in patients with severe heart failure. The CIBIS-II trial of bisoprolol was also halted early because all-cause mortality dropped significantly in the treatment group.11PubMed Central. The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction When the three were compared head-to-head, carvedilol edged out metoprolol tartrate (a shorter-acting formulation) for overall mortality in the COMET trial, though all three remain guideline-endorsed.12PubMed Central. The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
Mineralocorticoid receptor antagonists (MRAs) like spironolactone and eplerenone block aldosterone, the final hormone in the RAAS cascade. Both reduce death. A meta-analysis comparing the two found lower mortality rates with eplerenone among HFrEF patients, though eplerenone causes fewer hormonal side effects like breast tenderness.13PubMed Central. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis Potassium levels need monitoring with either drug, since both can raise it to dangerous levels, especially in people with impaired kidney function.
SGLT2 Inhibitors
The newest pillar comprises drugs originally developed for diabetes: the SGLT2 inhibitors dapagliflozin and empagliflozin. A pooled analysis of the two major trials (DAPA-HF and EMPEROR-Reduced), covering nearly 8,500 patients, showed a 26% reduction in the combined risk of cardiovascular death or first heart failure hospitalization and a 13% reduction in death from any cause.14The Lancet. Cardiorenal and mortality outcomes in patients with heart failure with reduced ejection fraction and or without type 2 diabetes: a prespecified meta-analysis of the DAPA-HF and EMPEROR-Reduced trials The benefits held up whether or not the patient had diabetes, which surprised many clinicians when the data first emerged. The same analysis also showed a reduction in worsening kidney outcomes, making SGLT2 inhibitors doubly valuable given how often kidney disease accompanies heart failure.
Getting All Four Drugs on Board Quickly
Historically, doctors introduced these medications one at a time, slowly up-titrating each over months before adding the next. Newer evidence suggests that starting all four pillars simultaneously or in rapid sequence produces better results. In the STRONG-HF trial, a high-intensity approach got patients to target doses of neurohormonal blockers far faster than usual care. At 90 days, roughly half the patients in the high-intensity group had reached target doses, compared to single-digit percentages in the control arm. By 180 days, the combined rate of death or hospitalization was about 15% in the rapid-start group compared to about 23% with usual care, a difference so large the trial was stopped early on the recommendation of its safety board.15PubMed Central. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy
The trade-off is that faster initiation comes with more side effects in the short term. Adverse event rates were higher in the intensive group. But the reduction in death and hospitalization outweighed those risks, and serious adverse events did not differ between groups. This has shifted clinical thinking toward getting patients on all four pillars as soon as safely possible, rather than perfecting one medication before starting the next.
Reverse Remodeling: Can the Heart Recover?
One of the more hopeful aspects of HFrEF is that the heart can, to a meaningful degree, heal. When effective therapy is sustained, the left ventricle often shrinks back toward normal size and pumping ability improves, a process called reverse remodeling. Each additional pillar of guideline-directed therapy a patient receives is linked to greater gains in EF and greater reductions in heart chamber volumes, and this benefit persists into older age.16Association of Age With Guideline-Directed Medical Therapy and Left Ventricular Reverse Remodeling. Association of Age With Guideline-Directed Medical Therapy and Left Ventricular Reverse Remodeling
Not every patient’s heart recovers to the same degree, and many never reach a normal EF. But meaningful improvement happens frequently enough that guidelines recommend re-checking EF after patients have been on optimized therapy for several months. Some people who were initially told they needed an implanted defibrillator find that their EF has improved above the device threshold, which can change the conversation about whether to proceed.
Implantable Devices: ICDs and CRT
When drug therapy alone is not enough to manage the risk of sudden death or the burden of symptoms, implantable devices come into play. An implantable cardioverter-defibrillator (ICD) monitors heart rhythm continuously and delivers a shock if it detects a life-threatening arrhythmia. The major trials (MADIT-II and SCD-HeFT) showed that ICDs reduce mortality in patients with an EF at or below 35%, with MADIT-II reporting a 31% relative reduction in death over five years in patients with ischemic heart disease.17PubMed Central. Devices in Heart Failure Patients—Who Benefits From ICD and CRT?
Cardiac resynchronization therapy (CRT) is a specialized pacemaker that coordinates the timing of the left and right ventricles. It is most helpful for patients whose electrical conduction is delayed, visible as a widened QRS complex on an electrocardiogram. Long-term follow-up from the RAFT trial, extending to a median of nearly 14 years, showed that CRT combined with defibrillation (CRT-D) provided a sustained survival advantage over an ICD alone in patients with reduced EF and a widened QRS.18PubMed. Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure Registry data also confirm that the benefits of ICD and CRT therapy apply equally to men and women, despite earlier uncertainty about whether women benefit from ICDs to the same degree.19PubMed. Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF
Kidney Disease, Iron Deficiency, and Other Comorbidities
Heart failure rarely travels alone. The interplay between the heart and the kidneys is especially tight. As the heart weakens, reduced blood flow to the kidneys triggers fluid retention, which worsens heart failure, which further impairs the kidneys. Chronic inflammation and scar tissue formation (fibrosis) appear to be shared drivers of decline in both organs, making this cycle particularly difficult to break.20Circulation. Cardiorenal Syndrome Revisited The kidney-protective effects observed with SGLT2 inhibitors are one reason those drugs have become such a valued part of the toolkit.
Iron deficiency is another common companion. Roughly half of heart failure patients are iron-deficient, and in HFrEF the consequences go beyond anemia: iron is critical for the energy-producing machinery inside heart muscle cells. A meta-analysis of trials giving intravenous iron to iron-deficient HFrEF patients found meaningful improvements in exercise capacity, quality of life, and EF, along with fewer heart failure hospitalizations and lower all-cause mortality, though not a reduction in all-cause hospitalization on its own.21PubMed Central. Intravenous iron for acute and chronic heart failure with reduced ejection fraction (HFrEF) patients with iron deficiency: An updated systematic review and meta-analysis A smaller trial of intravenous iron sucrose given during acute decompensation found that treated patients had significantly better symptom scores at four weeks.22PubMed Central. Intravenous Iron Sucrose for Acute Decompensated Heart Failure Patients with Reduced Ejection Fraction and Iron Deficiency The benefits appear specific to HFrEF; in preserved-EF heart failure, intravenous iron has not shown a similar payoff.23PubMed Central. Intravenous iron for iron deficiency in heart failure with preserved ejection fraction: A multivariate analysis
Exercise and Cardiac Rehabilitation
Telling someone with a weak heart to exercise might sound counterintuitive, but structured exercise training is one of the best-supported interventions in HFrEF. A systematic review and meta-analysis found that exercise programs improved peak oxygen consumption, six-minute walking distance, quality-of-life scores, and even EF in HFrEF patients, alongside meaningful reductions in natriuretic peptide levels, those same biomarkers that track how much stress the heart is under.24PubMed Central. Exercise Training in Heart failure with Preserved and Reduced Ejection Fraction: A Systematic Review and Meta-Analysis Cardiac rehabilitation programs, which combine supervised exercise with education and psychosocial support, have been shown to be highly cost-effective for reducing hospitalizations and improving quality of life in heart failure patients.25PubMed. Cardiac Rehabilitation and Heart Failure with Reduced Ejection Fraction: Pathophysiology, Benefits, and Precautions
Despite this evidence, referral rates to cardiac rehab for heart failure remain far lower than for patients recovering from heart attacks or bypass surgery. Part of the problem is patient perception: many people with HFrEF assume that exertion is dangerous for them. In reality, the danger runs the other direction. Prolonged inactivity accelerates the skeletal muscle wasting and deconditioning that make heart failure symptoms progressively worse. The key is that exercise should be graded and supervised, at least initially, with clear guidance on what to do if symptoms flare.
Newer Additions and Emerging Therapies
For patients who remain symptomatic despite the four pillars, a newer oral drug called vericiguat offers a modest additional benefit. In the VICTORIA trial of over 5,000 patients with worsening HFrEF, vericiguat reduced the combined endpoint of cardiovascular death or heart failure hospitalization from about 39% with placebo to about 36% over a median follow-up of roughly 11 months.26PubMed. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction The effect is smaller than what the four pillars deliver individually, but in a population that has already exhausted the standard options, any incremental gain matters. Early data also suggest vericiguat promotes reverse remodeling through a pathway that appears independent of the four pillars, meaning its structural benefits do not depend on whether other medications have been fully optimized.27European Heart Journal Supplements. STRUCTURAL REVERSE REMODELING WITH VERICIGUAT IN HFREF: IS THE BENEFIT DEPENDENT ON THE DEGREE OF BASELINE GUIDELINE–DIRECTED MEDICAL THERAPY OPTIMIZATION?
Implantable pulmonary artery pressure sensors represent another frontier. These small devices allow doctors to monitor fluid buildup remotely and adjust diuretic doses before symptoms escalate into a hospital admission. Multiple randomized trials have confirmed that pressure-guided management reduces heart failure hospitalizations.28PubMed Central. Hemodynamic Monitoring Devices in the Management of Outpatient Heart Failure The concept is straightforward: instead of waiting for a patient to gain weight or become breathless, the doctor sees rising pressures in real time and intervenes early.
Advanced Heart Failure and When to Consider Mechanical Support
A subset of HFrEF patients progress to advanced or end-stage disease despite maximal therapy. For these individuals, options narrow to heart transplantation or a left ventricular assist device (LVAD), a mechanical pump surgically implanted to help the failing ventricle push blood forward. LVADs can serve as a bridge while a patient waits for a donor heart, or as long-term “destination therapy” when transplant is not feasible. The trade-offs include surgical risk and ongoing complications such as infection, bleeding, and device clotting, which require careful monitoring and frequent follow-up.
Palliative care is an underused resource in advanced heart failure. The trajectory of HFrEF is unpredictable, marked by episodes of acute worsening interspersed with periods of stability, which makes timing end-of-life conversations difficult. Guidelines increasingly recommend integrating palliative support early in the disease course rather than reserving it for the final weeks of life. A multidisciplinary palliative approach has been shown to improve quality of life for both patients and their families throughout the illness.29PubMed. Palliative Care in Patients with Advanced Heart Failure
Socioeconomic Gaps in Treatment
Having effective therapies available does not guarantee that everyone receives them. Data from a multinational Asian registry found that patients in lower-income regions were significantly less likely to receive beta-blockers and device therapies, and that lower individual education and household income amplified the disparity even within a given country.30PubMed. Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia The consequences were tangible: higher socioeconomic status was associated with better quality of life and a lower risk of the combined outcome of death and hospitalization. These findings are consistent with patterns observed globally, where medication costs, clinic access, and health literacy all influence whether a patient ever gets started on the four-pillar regimen, let alone reaches target doses. The science of HFrEF treatment has advanced enormously, but the delivery of that science remains uneven.